Testing a new drug for lupus and rheumatoid arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study tests an investigational drug called SAR448501/DR-0201 in people with active lupus or rheumatoid arthritis who have not responded well to standard treatments. The goal is to see if the drug is safe and helps control disease activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have either systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA), diagnosed by standard criteria.
- For lupus: Your disease must be moderately to severely active, with a score of at least 8 on a standard activity scale, and you must have had a poor response to at least one treatment besides antimalarials.
- For rheumatoid arthritis: Your disease must be moderate to severe (based on joint counts and a disease activity score), and you must have tried and failed or not tolerated at least 2 prior drugs, including at least one biologic or targeted synthetic drug.
- You must use effective birth control during and for at least 140 days after the last dose. Women must have a negative pregnancy test before starting.
- You cannot have certain other serious health conditions, active infections, or have received certain strong medications or procedures within specific timeframes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injectable drug, HC022, for people with lupus or cutaneous lupus. It aims to see if the drug is safe, tolerable, and begins to work.
This study tests a new injectable medicine (SG301) for people with lupus (SLE) whose current treatments are not working well enough or cause side effects. It aims to see if this targeted therapy can better control lupus symptoms.
This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.
This trial tests a new drug called LY4298445 in healthy people and those with lupus or rheumatoid arthritis. It aims to see if the drug is safe and how the body processes it.
This trial tests an investigational drug called CPTX2309, given intravenously, for people with moderate to severe rheumatoid arthritis or systemic lupus erythematosus. It aims to see if the drug is safe and effective.
This study tests a new drug, MK-1045, for people with lupus or rheumatoid arthritis. It aims to see if the drug is safe and how it affects your condition.
Hear when a new Systemic Lupus Erythematosus (SLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.